SC
EVOK

Sophrosyne Capital’s Evoke Pharma EVOK Stock Holding History

Sophrosyne Capital’s Portfolio EVOK Stock Details EVOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-340
Closed -$397K – 65
2014
Q2 		$397K Hold
340
– – 0.4% 42
2014
Q1 		$411K Buy
+340
New +$485K 0.36% 50

Other funds holding EVOK

OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 28.54% 1-Year Est. Return
GSC
Ground Swell Capital Folly Beach, South Carolina $92.6M AUM 41.64% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Sophrosyne Capital's EVOK Position: Q3 2014 in Review

Sophrosyne Capital sold out of Evoke Pharma (EVOK) in Q3 2014, closing a stake of 340 shares — an estimated $397K sold.

Sophrosyne Capital first reported a position in EVOK in Q1 2014 and held it in 2 quarters. The position peaked at $411K in Q1 2014. 11 funds tracked by Wall St. Rank hold EVOK as of Q3 2014.

  • Sophrosyne Capital reported no remaining Evoke Pharma position as of Q3 2014 after selling out during the quarter.
  • Sophrosyne Capital sold 340 Evoke Pharma shares in Q3 2014, an estimated $397K.
  • Sophrosyne Capital first reported a position in Evoke Pharma in Q1 2014 and held it in 2 quarters.
  • Sophrosyne Capital's Evoke Pharma position peaked at $411K in Q1 2014.
  • 11 funds tracked by Wall St. Rank held Evoke Pharma as of Q3 2014.

Based on Sophrosyne Capital's 13F filing for Q3 2014, filed 14 Nov 2014.